analytical standard

42-O-(2-Hydroxyethyl)rapamycin, CERTICAN
Empirical Formula (Hill Notation):
CAS Number:
Molecular Weight:
MDL number:
PubChem Substance ID:
Pricing and availability is not currently available.


analytical standard


≥95% (HPLC)

shelf life

limited shelf life, expiry date on the label


HPLC: suitable
gas chromatography (GC): suitable

Featured Industry

Forensics and Toxicology
Pharmaceutical (small molecule)

storage temp.


SMILES string




InChI key


Gene Information

human ... FKBP1A(2280)

Looking for similar products? Visit Product Comparison Guide


Bottomless glass bottle. Contents are inside inserted fused cone.

Analysis Note

Exact concentration and expiry date can be found on the certificate, included in each package.

Legal Information

CERTICAN is a registered trademark of Novartis AG


Health hazardEnvironment

Signal Word


Hazard Statements

Precautionary Statements

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves

Hazard Codes


Risk Statement


Safety Statement



UN 3077 9 / PGIII

WGK Germany


Certificate of Analysis
Certificate of Origin
Masahiro Matsuki et al.
Cancer science, 108(4), 763-771 (2017-01-21)
The combination of lenvatinib, a multiple receptor tyrosine kinase inhibitor, plus everolimus, a mammalian target of rapamycin (mTOR) inhibitor, significantly improved clinical outcomes versus everolimus monotherapy in a phase II clinical study of metastatic renal cell carcinoma (RCC). We investigated...
Takashi Muramatsu et al.
JACC. Cardiovascular interventions, 6(3), 247-257 (2013-03-23)
The aim of this study was to investigate the incidence and clinical sequelae of small side branch occlusion (SBO) after Absorb (Abbott Vascular, Santa Clara, California) bioresorbable vascular scaffold (BVS) implantation. The thicker strut of metallic stents potentially contributes to...
Robert J Motzer et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(25), 2765-2772 (2014-07-23)
A multicenter, randomized phase II trial, RECORD-3, was conducted to compare first-line everolimus followed by sunitinib at progression with the standard sequence of first-line sunitinib followed by everolimus in patients with metastatic renal cell carcinoma. RECORD-3 used a crossover treatment...
Alfonso Ielasi et al.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 89(7), 1129-1138 (2016-10-25)
To assess the feasibility and the clinical results following a prespecified bioresorbable vascular scaffold (Absorb BVS) implantation strategy in ST-elevation myocardial infarction (STEMI) patients. Concerns raised about the BVS safety in STEMI setting because a not negligible thrombosis rate was...
Simron Singh et al.
Neuroendocrinology, 106(3), 211-220 (2017-05-30)
The RADIANT-4 randomized phase 3 study demonstrated significant prolongation of median progression-free survival (PFS) with everolimus compared to placebo (11.0 [95% CI 9.2-13.3] vs. 3.9 [95% CI 3.6-7.4] months) in patients with advanced, progressive, nonfunctional gastrointestinal (GI) and lung neuroendocrine...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.